Skip to content

Efficacy and safety of low molecular weight heparin in the prevention of acute necrotizing pancreatitis complicated with portal vein thrombosis: a multicenter, prospective, double-blind, randomized controlled trial

Efficacy and safety of low molecular weight heparin in the prevention of acute necrotizing pancreatitis complicated with portal vein thrombosis: a multicenter, prospective, double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023372
Enrollment
Unknown
Registered
2019-05-25
Start date
2019-06-30
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute necrotizing pancreatitis

Interventions

A group:Low molecular weight heparin

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Aged = 18 and <85 years; 2) Meet AP diagnostic criteria; 3) Acute pancreatitis onset = 7 days; 4) CT diagnoses pancreatic necrosis and/or mixed necrosis.

Exclusion criteria

Exclusion criteria: 1) pregnant or lactating women; 2) any part of vascular thrombosis before enrollment; 3) severe active bleeding; 4) indications for emergency laparotomy: such as peritoneal organ perforation, abdominal cavity syndrome that is difficult to correct with conservative treatment; 5) those who are allergic to heparin; 6) refusing to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Incidence of portal vein thrombosis ;

Secondary

MeasureTime frame
Incidence of pancreatic portal hypertension ;Incidence of abdominal bleeding;Incidence of organ failure;Mortality;Total hospital days;Hospital charge;Adverse event;

Countries

China

Contacts

Public ContactNonghua Lv

The First Affiliated Hospital of Nanchang University

lunonghua@ncu.edu.cn+86 0791-88692705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026